Incyte Corp. XNAS: INCY

Incyte Corp. Live Stock Price Today, Share Analysis and Chart

Name: Incyte Corp.: Is Infosys Ltd. worth buying?
Item: Incyte Corp.
Rating: 2.049874875
Author: Trendlyne DVM scores

Momentum Trap

about

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheuma...

76.83 -0.72 (-0.93%)

43.45% Gain from 52W Low

120.9K

XNAS Volume

XNAS 31 Jul, 2025 9:44 AM (EDT)

Board Meeting

The latest board meeting for Incyte Corp. took place on 30 Jul 2025, for the purpose of Incyte Corp Second Quarter Earnings Results for 2025 See details

Low Financial Strength

33.3 / 100

Mid Valuation

34.3 / 100

Technically Moderately Bullish

63.0 / 100

Momentum Trap These stocks are with bad quality but mid-range Valuation. However, their good technical scoring may generate some interest amongst the audience. View Similar Embed DVM

1Yr Price target upside is 3%

22 analysts

Incyte Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Incyte Corp. Live Stock Price Today, Share Analysis and Chart

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheuma...

43.45% Gain from 52W Low

SWOT Analysis

Incyte Live Price Chart